Literature DB >> 2528582

An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties.

W P Arend1, F G Joslin, R C Thompson, C H Hannum.   

Abstract

Previous studies have described a 22 kD IL-1 inhibitor in the supernatant of human monocytes cultured on adherent immune complexes (J. Immunol. 134:3868, 1985). The studies reported herein further detail the conditions of production and biological properties of this IL-1 inhibitor. The inhibitor was produced by human monocytes cultured on adherent human IgG with maximal production between 8 and 24 hr. The IL-1 inhibitor was not performed in the cells but required transcription and new protein synthesis. The inhibitor blocked IL-1 augmentation of PHA-induced murine thymocyte proliferation but not IL-2-induced stimulation of CTLL or HT-2 cell lines. In addition, the inhibitor blocked IL-1-stimulated collagenase production from rabbit articular chondrocytes and IL-1-induced PGE2 production from human fibroblasts and synovial cells. The IL-1 inhibitor was not transforming growth factor beta (TGF beta) as determined by: the failure of anti-TGF beta antibodies to reduce IL-1 inhibitory activity, the separation of TGF beta from the IL-1 inhibitor by ion exchange chromatography, and the failure of TGF beta to inhibit IL-1-induced PGE2 production from synovial cells. IL-1 and the inhibitor showed no immunological cross-reactivity by Western blot analysis. The inhibitor specifically blocked binding of IL-1 to its receptor on the murine thymoma cell line EL4-6.1. These results indicate that a specific inhibitor of IL-1-induced immune and inflammatory cell responses is produced by monocytes cultured on adherent immune complexes or adherent IgG. This IL-1 inhibitor may be of importance in modulating the effects of IL-1 in the monocyte microenvironment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2528582

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis.

Authors:  B Kirkham
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

3.  Is there a causal role for IL-1 in postmenopausal bone loss?

Authors:  R Pacifici
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

4.  Selective and early increase of IL-1 inhibitors, IL-6 and cortisol after elective surgery.

Authors:  F Di Padova; C Pozzi; M J Tondre; R Tritapepe
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

5.  cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium.

Authors:  S Haskill; G Martin; L Van Le; J Morris; A Peace; C F Bigler; G J Jaffe; C Hammerberg; S A Sporn; S Fong
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

6.  An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance.

Authors:  B E Henricson; R Neta; S N Vogel
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

7.  Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.

Authors:  R B Kimble; J L Vannice; D C Bloedow; R C Thompson; W Hopfer; V T Kung; C Brownfield; R Pacifici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

8.  Mouse interleukin-1 receptor antagonist induced by Actinobacillus actinomycetemcomitans lipopolysaccharide blocks the effects of interleukin-1 on bone resorption and osteoclast-like cell formation.

Authors:  T Nishihara; Y Ohsaki; N Ueda; N Saito; G R Mundy
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  Comparison of peripheral blood leukocyte kinetics after live Escherichia coli, endotoxin, or interleukin-1 alpha administration. Studies using a novel interleukin-1 receptor antagonist.

Authors:  A S Hawes; E Fischer; M A Marano; K J Van Zee; C S Rock; S F Lowry; S E Calvano; L L Moldawer
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

10.  Differential interleukin-1 receptor antagonism on pancreatic beta and alpha cells. Studies in rodent and human islets and in normal rats.

Authors:  U Zumsteg; J I Reimers; F Pociot; L Mørch; S Helqvist; M Brendel; R Alejandro; T Mandrup-Poulsen; C A Dinarello; J Nerup
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.